밍키넷: 해외 성인 컨텐츠 제공 사이트와 국내 법적 이슈 무료야동
페이지 정보
작성자 화수여라 쪽지보내기 메일보내기 자기소개 아이디로 검색 전체게시물 작성일25-11-19 21:26조회5회 댓글0건
관련링크
-
http://18.kissjav.life
0회 연결
-
http://42.kissjav.click
0회 연결
본문
밍키넷: 새로운 온라인 커뮤니티의 매력과 활용법
밍키넷이란 무엇인가?
밍키넷의 주요 기능과 특징
밍키넷을 활용하는 방법
밍키넷의 장단점 분석
밍키넷의 미래 전망
밍키넷이란 무엇인가?
밍키넷의 주요 기능과 특징
밍키넷은 다음과 같은 주요 기능과 특징을 가지고 있습니다:
익명성 보장: 사용자들은 익명으로 활동할 수 있어, 부담 없이 의견을 나눌 수 있습니다.
다양한 주제의 게시판: IT, 게임, 생활, 취미 등 다양한 주제의 게시판이 마련되어 있습니다.
실시간 채팅: 실시간으로 다른 사용자들과 채팅을 할 수 있는 기능도 제공됩니다.
밍키넷을 활용하는 방법
밍키넷을 효과적으로 활용하기 위해서는 다음과 같은 방법을 추천합니다:
관심 있는 주제의 게시판 찾기: 자신의 관심사에 맞는 게시판을 찾아 활동하면 더 많은 정보를 얻을 수 있습니다.
적극적인 참여: 질문을 하거나 의견을 나누는 등 적극적으로 참여하면 더 많은 지식을 얻을 수 있습니다.
커뮤니티 규칙 준수: 밍키넷의 규칙을 준수하며, 다른 사용자들과의 원활한 소통을 유지하는 것이 중요합니다.
밍키넷의 장단점 분석
장점: 익명성 보장, 다양한 주제의 게시판, 실시간 채팅 기능 등이 있습니다.
단점: 익명성으로 인한 부작용, 일부 게시판의 관리 미흡 등이 있습니다.
밍키넷의 미래 전망
키워드: 밍키넷, 온라인 커뮤니티, 익명성, 게시판, 실시간 채팅, 밍키넷 같은 사이트, 26
This article was released as Pharm Edaily Premium Content on November 12, 2025, at 6:05 PM.
[Kim Saemi, Edaily Reporter] On the 12th, ABL Bio led a general market rally as it secured a major deal worth 3.8 trillion KRW with Eli Lilly. The biotech sector saw strong demand, with rising interest in companies like Sinteca Bio, which is benefitting from government suppo 릴게임갓 rt. Meanwhile, Genome & Company plans to focus on antibody-drug conjugate (ADC) development after announcing results of a domestic Phase 2 trial for its microbiome-based cancer immunotherapy, GEN-001. 릴게임야마토
ABL Bio’s 3.8 Trillion KRW ‘Big Deal’… What’s Next for Tech Exports?
According to KG Zeroin MP Doctor(formerly MarketPoint), ABL Bio’s stock surged by 29.95%, closing at 126,700 K 오션파라다이스릴게임 RW, a rise of 29,200 KRW compared to the previous day.
ABL Bio Stock Trend on the 12th (Source: KG Zeroin MP Doctor)
바다이야기#릴게임 At 10:55 AM that day, ABL Bio announced a deal with Eli Lilly and Company, granting exclusive rights to develop and commercialize multiple undisclosed drug candidates using its “Grabody-B” pl 야마토게임예시 atform technology. The deal is worth a total of 3.8 trillion KRW. Earlier in April, ABL Bio also signed a technology transfer deal with GlaxoSmithKline (GSK) for up to 4.1 trillion KRW using the Grabody-B platform. This news immediately propelled ABL Bio‘s stock to its daily upper limit.
The technology transfer news attracted attention to the biotech sector, with companies such as Alteogen, LigaChem Biosciences, Olix Pharmaceuticals, and Peptaron being seen as potential candidates for future tech exports.
Alteogen, the top KOSDAQ market cap company, has mentioned that one or two technology transfer deals could be expected by year-end. Investors are speculating that deals involving bispecific antibodies or ADC technologies might be announced soon. Alteogen’s stock rose by 8.04%, reaching a new 52-week high at 551,000 KRW.
Interest in LigaChem Biosciences, known as a leader in technology exports, also increased, with the stock soaring by 17.56%, closing at 170,700 KRW, also a new 52-week high. Olix Pharmaceuticals, which had been selected by Eli Lilly for a partnership, also surged by 15.16%, closing at 139,000 KRW, setting a new 52-week high.
Given the size of the deal with Eli Lilly, market attention also shifted to Peptaron, which signed a technology evaluation contract with Eli Lilly in October last year. This evaluation is expected to conclude by December, and investors had hoped for a tech export deal by year-end. Delays into next year have caused fluctuations in the stock. However, today, Peptron’s stock rose by 28,000 KRW (10.53%), closing at 294,000 KRW, as expectations of a technology transfer were once again reflected in the market.
Sinteca Bio Hits Upper Limit as AI Drug Stocks Surge on Government Support
At the beginning of trading, Sinteca Bio saw its stock hit the upper limit, boosting the AI-driven drug development sector. By 9:04 AM, Sinteca Bio’s stock had surged by 29.77%, reaching 5,470 KRW, and maintained its position at the upper limit for the rest of the day. AI drug developer OncoCross also rose by 16.76%, closing at 12,330 KRW.
SyntekaBio Stock Trend on the 12th (Source: KG Zeroin MP Doctor)
The surge in Sinteca Bio’s stock was driven by news that the company is leveraging its AI platform and bio data center infrastructure to develop new treatments. Sinteca Bio’s strategy of advancing from single-target drugs to multi-target, personalized treatments in line with global pharmaceutical trends appears to have driven investor optimism.
AI drug developers have been seeing volatile stock movements recently. On the 11th, Pharose Eye Bio surged to the upper limit after its drug candidate for acute myeloid leukemia (AML) was listed by the World Health Organization (WHO).
The strong performance of AI drug developers is seen as a reflection of the market’s expectations that government support will translate into tangible results. Recently, several key government agencies, including the Ministry of Health and Welfare, the Ministry of Science and ICT, and the Ministry of SMEs and Startups, have launched AI-focused drug development projects.
The Ministry of Health and Welfare announced plans to launch the K-AI drug development R&D project on the 5th, which is expected to rapidly advance domestic AI drug candidates into clinical stages through large-scale national projects. The Ministry of Science and ICT is investing 18.2 billion KRW to launch an AI-specialized foundation model project from this month through September next year, with participation from companies such as Lunit and SK Biopharm.
A representative from Sinteca Bio commented, “The overall rise in AI drug development stocks seems to be benefiting from sector-wide demand.”
Genome & Company Shifts Focus to ADC After Microbiome Development
At 1:22 PM, Genome & Company released the results of its Phase 2 clinical trial for GEN-001, a treatment for stomach cancer, in Korea. Following the announcement, the company’s stock rose by 18.44%, reaching a high of 3,494 KRW, surpassing the 52-week trading volume record.
Genome & Company Stock Trend on the 12th (Source: KG Zeroin MP Doctor)
The results showed that 8 out of 42 patients (19%) had a partial response (PR), and the median progression-free survival (PFS) was 1.71 months. The overall survival (OS) was 7.79 months, with a 12-month survival rate of 33%.
While the results indicated some positive responses, particularly in terms of response durability among a small subset of patients, the data did not show significant benefits in terms of OS or PFS.
Despite these mixed results, the company’s stock ended the day 9.83% higher, closing at 3,240 KRW.
Genome & Company has stated that it does not plan to conduct additional clinical trials for GEN-001 but may continue to develop it with overseas partners. The company’s shift in focus towards ADC technology is expected to limit the impact of the GEN-001 trial results on its overall valuation. A company representative noted, “Genome & Company does not plan to continue further clinical trials for GEN-001, but if we find overseas partners, we could continue development.”
김새미 (bird@edaily.co.kr)
[Kim Saemi, Edaily Reporter] On the 12th, ABL Bio led a general market rally as it secured a major deal worth 3.8 trillion KRW with Eli Lilly. The biotech sector saw strong demand, with rising interest in companies like Sinteca Bio, which is benefitting from government suppo 릴게임갓 rt. Meanwhile, Genome & Company plans to focus on antibody-drug conjugate (ADC) development after announcing results of a domestic Phase 2 trial for its microbiome-based cancer immunotherapy, GEN-001. 릴게임야마토
ABL Bio’s 3.8 Trillion KRW ‘Big Deal’… What’s Next for Tech Exports?
According to KG Zeroin MP Doctor(formerly MarketPoint), ABL Bio’s stock surged by 29.95%, closing at 126,700 K 오션파라다이스릴게임 RW, a rise of 29,200 KRW compared to the previous day.
ABL Bio Stock Trend on the 12th (Source: KG Zeroin MP Doctor)
바다이야기#릴게임 At 10:55 AM that day, ABL Bio announced a deal with Eli Lilly and Company, granting exclusive rights to develop and commercialize multiple undisclosed drug candidates using its “Grabody-B” pl 야마토게임예시 atform technology. The deal is worth a total of 3.8 trillion KRW. Earlier in April, ABL Bio also signed a technology transfer deal with GlaxoSmithKline (GSK) for up to 4.1 trillion KRW using the Grabody-B platform. This news immediately propelled ABL Bio‘s stock to its daily upper limit.
The technology transfer news attracted attention to the biotech sector, with companies such as Alteogen, LigaChem Biosciences, Olix Pharmaceuticals, and Peptaron being seen as potential candidates for future tech exports.
Alteogen, the top KOSDAQ market cap company, has mentioned that one or two technology transfer deals could be expected by year-end. Investors are speculating that deals involving bispecific antibodies or ADC technologies might be announced soon. Alteogen’s stock rose by 8.04%, reaching a new 52-week high at 551,000 KRW.
Interest in LigaChem Biosciences, known as a leader in technology exports, also increased, with the stock soaring by 17.56%, closing at 170,700 KRW, also a new 52-week high. Olix Pharmaceuticals, which had been selected by Eli Lilly for a partnership, also surged by 15.16%, closing at 139,000 KRW, setting a new 52-week high.
Given the size of the deal with Eli Lilly, market attention also shifted to Peptaron, which signed a technology evaluation contract with Eli Lilly in October last year. This evaluation is expected to conclude by December, and investors had hoped for a tech export deal by year-end. Delays into next year have caused fluctuations in the stock. However, today, Peptron’s stock rose by 28,000 KRW (10.53%), closing at 294,000 KRW, as expectations of a technology transfer were once again reflected in the market.
Sinteca Bio Hits Upper Limit as AI Drug Stocks Surge on Government Support
At the beginning of trading, Sinteca Bio saw its stock hit the upper limit, boosting the AI-driven drug development sector. By 9:04 AM, Sinteca Bio’s stock had surged by 29.77%, reaching 5,470 KRW, and maintained its position at the upper limit for the rest of the day. AI drug developer OncoCross also rose by 16.76%, closing at 12,330 KRW.
SyntekaBio Stock Trend on the 12th (Source: KG Zeroin MP Doctor)
The surge in Sinteca Bio’s stock was driven by news that the company is leveraging its AI platform and bio data center infrastructure to develop new treatments. Sinteca Bio’s strategy of advancing from single-target drugs to multi-target, personalized treatments in line with global pharmaceutical trends appears to have driven investor optimism.
AI drug developers have been seeing volatile stock movements recently. On the 11th, Pharose Eye Bio surged to the upper limit after its drug candidate for acute myeloid leukemia (AML) was listed by the World Health Organization (WHO).
The strong performance of AI drug developers is seen as a reflection of the market’s expectations that government support will translate into tangible results. Recently, several key government agencies, including the Ministry of Health and Welfare, the Ministry of Science and ICT, and the Ministry of SMEs and Startups, have launched AI-focused drug development projects.
The Ministry of Health and Welfare announced plans to launch the K-AI drug development R&D project on the 5th, which is expected to rapidly advance domestic AI drug candidates into clinical stages through large-scale national projects. The Ministry of Science and ICT is investing 18.2 billion KRW to launch an AI-specialized foundation model project from this month through September next year, with participation from companies such as Lunit and SK Biopharm.
A representative from Sinteca Bio commented, “The overall rise in AI drug development stocks seems to be benefiting from sector-wide demand.”
Genome & Company Shifts Focus to ADC After Microbiome Development
At 1:22 PM, Genome & Company released the results of its Phase 2 clinical trial for GEN-001, a treatment for stomach cancer, in Korea. Following the announcement, the company’s stock rose by 18.44%, reaching a high of 3,494 KRW, surpassing the 52-week trading volume record.
Genome & Company Stock Trend on the 12th (Source: KG Zeroin MP Doctor)
The results showed that 8 out of 42 patients (19%) had a partial response (PR), and the median progression-free survival (PFS) was 1.71 months. The overall survival (OS) was 7.79 months, with a 12-month survival rate of 33%.
While the results indicated some positive responses, particularly in terms of response durability among a small subset of patients, the data did not show significant benefits in terms of OS or PFS.
Despite these mixed results, the company’s stock ended the day 9.83% higher, closing at 3,240 KRW.
Genome & Company has stated that it does not plan to conduct additional clinical trials for GEN-001 but may continue to develop it with overseas partners. The company’s shift in focus towards ADC technology is expected to limit the impact of the GEN-001 trial results on its overall valuation. A company representative noted, “Genome & Company does not plan to continue further clinical trials for GEN-001, but if we find overseas partners, we could continue development.”
김새미 (bird@edaily.co.kr)
댓글목록
등록된 댓글이 없습니다.
